These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38831004)

  • 1. Strength of selection in lung tumors correlates with clinical features better than tumor mutation burden.
    Gorlov IP; Gorlova OY; Tsavachidis S; Amos CI
    Sci Rep; 2024 Jun; 14(1):12732. PubMed ID: 38831004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma.
    Cheng X; Yin H; Fu J; Chen C; An J; Guan J; Duan R; Li H; Shen H
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1027-1035. PubMed ID: 30810839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies.
    Shen E; Xiu J; Bentley R; López GY; Walsh KM
    Clin Lung Cancer; 2020 Nov; 21(6):e523-e527. PubMed ID: 32414627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer.
    Zhang N; Wu J; Yu J; Zhu H; Yang M; Li R
    Clin Lung Cancer; 2020 May; 21(3):e151-e163. PubMed ID: 31734072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of lung cancer drivers by comparison of the observed and the expected numbers of missense and nonsense mutations in individual human genes.
    Gorlova OY; Kimmel M; Tsavachidis S; Amos CI; Gorlov IP
    Oncotarget; 2022; 13():756-767. PubMed ID: 35634240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
    Rekhtman N; Tafe LJ; Chaft JE; Wang L; Arcila ME; Colanta A; Moreira AL; Zakowski MF; Travis WD; Sima CS; Kris MG; Ladanyi M
    Mod Pathol; 2013 Apr; 26(4):511-22. PubMed ID: 23196793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
    Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
    Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM.
    Ma J; Setton J; Morris L; Albornoz PB; Barker C; Lok BH; Sherman E; Katabi N; Beal K; Ganly I; Powell SN; Lee N; Chan TA; Riaz N
    Oncotarget; 2017 Feb; 8(6):10312-10323. PubMed ID: 28055970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
    Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
    J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
    Choi M; Kadara H; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Kim K; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Herbst RS; Wistuba II
    Ann Oncol; 2017 Jan; 28(1):83-89. PubMed ID: 28177435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations.
    Husgafvel-Pursiainen K; Karjalainen A; Kannio A; Anttila S; Partanen T; Ojajärvi A; Vainio H
    Am J Respir Cell Mol Biol; 1999 Apr; 20(4):667-74. PubMed ID: 10100998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-exome sequencing to identify novel somatic mutations in squamous cell lung cancers.
    Zheng CX; Gu ZH; Han B; Zhang RX; Pan CM; Xiang Y; Rong XJ; Chen X; Li QY; Wan HY
    Int J Oncol; 2013 Sep; 43(3):755-64. PubMed ID: 23799614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
    Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases.
    Evans M; O'Sullivan B; Smith M; Hughes F; Mullis T; Trim N; Taniere P
    Pathol Oncol Res; 2019 Oct; 25(4):1401-1409. PubMed ID: 30094734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
    Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
    Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
    Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
    J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiles and transcriptomic microenvironments in 2 patients with synchronous lung adenocarcinoma and lung squamous cell carcinoma: a case report.
    Wu L; Kang P; Tao S; Zhao Z; Chen L; Xiao Y; Tan Q
    BMC Med Genomics; 2020 Jan; 13(1):15. PubMed ID: 32005243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple mutations of lung squamous cell carcinoma shared common mechanisms.
    Li Q; Hou J; Hu Z; Gu B; Shi Y
    Oncotarget; 2016 Nov; 7(48):79629-79636. PubMed ID: 27835590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.